Skip to main content
Egyptian Rheumatology and Rehabilitation

Table 4 Key clinical questions used to develop the guideline

From: Egyptian guidelines for the treatment of Rheumatoid Arthritis — 2022 update

1. What are the general considerations about RA diagnosis and assessment?

2. What is the meaning of disease remission and low disease activity?

3. How to monitor RA?

4. What is the target of treatment (how to treat to target?)

5. What is the role of patient communication and shared decision in standard care?

6. How to use the csDMARDs in RA management?

7. How to use the bDMARDs and tsDMARDs in RA management?

8. How to switch between RA therapies?

9. When and how to taper drug in RA management?

10. How to personalize the patient care?

11. What is the non-pharmacological management in RA?

12. What is the role of self-management in the treatment of RA?

13. When to refer to surgery in RA patients?

  1. SR Systematic review, RCT Randomised controlled trial, cDMARD Conventional disease-modifying antirheumatic drug, csDMARDs Conventional synthetic disease-modifying antirheumatic drugs, bDMARDs Biologic disease modifying antirheumatic drugs, boDMARDs Bio-originator disease modified antirheumatic drugs, bsDMARDs Bio-similar disease-modifying antirheumatic drugs, tsDMARDs Target synthetic disease-modifying antirheumatic drugs
Back to article page